- Mingshi Optima Fund can help accurately manage all kinds of short and long equities listed in Mainland China.
- This launch has been considered to be China’s most crucial launch in 2020.
Despite the coronavirus scare, companies have been taking strategic initiatives to augment their stance in the global landscape. A vital testament for the same is offered by Asia’s prominent fund firm, OPIM (OP Investment Management Limited), which has reportedly announced establishing a partnership with Shanghai Mingshi Investment Management. This partnership is aimed at launching Mingshi China Optima Master Fund along with 2 feeder funds that invest all assets into the Master Fund while operating for the benefit of the U.S tax exempt investors and several other non- U.S eligible investors.
According to official sources, the motive behind this launch is to actively and accurately manage all types of short and long equities listed in mainland China, accessed through market access products issued by RQFIIs or QFIIs. The team, together, incorporates branded factor models and quantitative research methodologies aiming at absolute returns based on years of track record of similar profile onshore.
Commenting on the launch, Alvin Fan, the CEO of OPIM reportedly stated that the China A-share opportunity has potentially spurred the demand for effective long-short strategies which not only produce significant alpha, but also protect it. He further adds that the company is delighted to partner Mingshi owing to its outstanding multi-year track record established by exceptional R&D team. Further, the recently launched Mingshi’s Optima is undeniably the region’s most important launch in 2020.
On the other hand, the Co-Founder and Head of Strategy of Mingshi, Yuan Yu quoted that the company has been closely working with OPIM over the last year for this strategic launch. He adds that the management is intensely focused on ensuring institutional grade product offshore similar to that of onshore.
For uninitiated, established in 2010, Mingshi is one of the veteran quantitative firms boasting of a strong research and development team in Shanghai, China.